Anreicherung von DL-3-¹²³I-Jod-α-Methyltyrosin in Hirntumorrezidiven

Zusammenfassung

DL-3-¹²³l-Jod-α-Methyltyrosin (¹²³I-JMT) ist ein Radiopharmakon, dessen Anreicherung in Hirntumoren mit SPECT nachweisbar ist. 20 Untersuchungen mit ¹²³I-JMT-SPECT wurden an 16 Patienten nach neurochirurgischen Operationen von Hirntumoren durchgeführt (Tumorlokalisation des Primärtumors aus CT/NMR-Bildern). Die Auswertung in ROI-Technik (Tumor/restliche Schicht) erfaßte die Tumor/Nichttumor-Verhältnisse (T/NT). In 17 Fällen lag ein Rezidiv- oder Resttumor vor. 14/17 waren durch erhöhten Uptake (T/NT 1,43-2,25) nachweisbar. Die Ergebnisse wurden mit CT und/oder NMR-Bildern verglichen und am weiteren Verlauf oder durch Rezidiv-Operationen (6/14) validiert. Alle 3 tumorfreien Patienten (Nachbeobachtungszeit 6-24 Monate) hatten einen negativen Scan; dies wurde durch CT- und NMR-Befunde bestätigt. Mit der ¹²³l-JMT-Szinti-graphie steht eine CT und NMR ergänzende nuklearmedizinische Methode zur Verfügung. Sie sollte bei unklaren neuroradiologischen oder klinischen Befunden durchgeführt werden und kann dazu beitragen, daß die Diagnose eines Rezidivs früher gestellt und eine entsprechende Therapie eingeleitet wird.

Summary

DL-3-¹²³l-iodo-α-methyltyrosine (¹²³I-IMT) is a radiopharmacon which concentrates in brain tumors and can be employed in SPECT. We performed 20 studies in 16 patients after neurosurgery for malignant brain tumors (localization of the primary tumor by CT/MRI). Tumor/non-tumor ratios (T/NT) were calculated in ROI-technique. In 17 cases there was a recurrence or tumor remnant. 14/17 were detectable by increased uptake (T/NT 1.43-2.25). The scans were correlated with CT/MRI studies and validated by biopsy (6/14) or follow-up. All 3 patients without recurrence (neuroradiological follow-up over 6-24 months) had a negative scan. ¹²³I-IMT scintigraphy provides complementary information to CT and MRI. In equivocal neuroradiological or clinical cases it may be valuable in the detection of tumor recurrences and allows an earlier onset of therapy.

Schlüsselwörter

Hirntumoren - SPECT - Jod-a-Methyltyrosin (¹²³I-JMT)

Keywords

Brain tumors - SPECT - iodo-a-methyltyrosine (¹²³I-IMT)

• LITERATUR

• 1 Ammirati M, Galicich JH, Arbit EYL. Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 1987; 21: 607-13.
• 2 Bergström M, Collins VP, Ehrin E. et al. Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [⁶⁸Ga]EDTA,[¹¹C]Glucose and [¹¹C]Methio-nin. J Comput Assist Tomogr 1983; 7: 1062-6.
• 3 Biersack HJ, Coenen HH, Stöcklin G. et al. Imaging of brain tumors with L-3-[¹²³I]Iodo-α-Methyl tyrosine and SPECT. J Nucl Med 1989; 30: 110-2.
• 4 Bockslaff H, Spitznas M, Hahn IGK. Non-contact detection of experimental amelano-tic ocular melanoma with L-3-¹²³I Iodo-α-Methyl Tyrosine. Arch Klin Ophthalmol 1981; 217: 255-66.
• 5 Bolster JM, Vaalburg W, Paans AMJ. et al. Carbon-11 labelled tyrosine to study tumor metabolism by positron emission tomography (PET). Eur J Nucl Med 1986; 12: 321-4.
• 6 Coenen HH, Kling PGS. Cerebral metabolism of L-[2-¹⁸F] fluorotyrosine, a new PET tracer of protein synthesis. J Nucl Med 1989; 30: 1367-72.
• 7 Di Chiro G, DeLaPaz RL, Brooks RA. et al. Glucose utilization of cerebral gliomas measured by [¹⁸F] fluorodeoxyglucose and positron emission tomography. Neurology 1982; 32: 1323-9.
• 8 Elster AD, DA D. Cranial postoperative site: Assessment with contrastenhanced MR imaging. Radiology 1990; 174: 93-8.
• 9 Forsting M, Albert FK, Kunze S, Adams HR, Zenner DKS. Extirpation of glioblastomas: MR and CT follow-up of residual tumor and regrowth patterns. Am J Neuroradiol 1993; 14: 77-87.
• 10 Guth-Tougelidis B, Müller S, Mehdorn M, Machulla HJ, Knust EJ. I-123-α-Methyl-Tyrosin in der postoperativen Nachsorge von Patienten mit Hirntumoren. Nucl-Med 1990; 29: A16.
• 11 Guth-Tougelidis B, Müller S, Mehdorn M. et al. Anreicherungsverhalten von Hirntumoren mit I-123-α-Methyl-Tyrosin. Nucl-Med 1989; 28: A35.
• 12 Hübner KF, Purvis TJ, Mahaley Jr SM. et al. Brain tumor imaging by positron emission tomography using ¹¹C-labeled amino acids. J Comput Assist Tomogr 1982; 6: 544-50.
• 13 Kawai K, Fujibayashi Y, Saji H, Konishi JAY. New radioiodinated radiopharmaceutical for cerebral amino acid transport studies: L-3-[¹²³I]Iodo-α-methyl tyrosine. J Nucl Med 1988; 29: P778.
• 14 Kazner E, Wende S, Grumme T, Stochdorph O, Felix RCC. Computer- und Kernspintomographie intrakranieller Tumoren aus klinischer Sicht. Berlin, Heidelberg: Springer; 1990: 53 ff.
• 15 Kloss G, Leven M. Accumulation of radioiodinated tyrosin dérivâtes in the adrenal medulla and in melanomas. Eur J Nucl Med 1979; 4: 179-86.
• 16 Kloster G, Bockslaff H. L-3-¹²³I-α-methyltyrosine for melanoma detection: a comparative evaluation. Int J Nucl Med Biol 1982; 9: 259-69.
• 17 Knust EJ, Dutschka K, Machulla HJ. Radiopharmaceutical preparation of 3-¹²T-α-methyltyrosine for nuclearmedical applications. J Radioanal Nucl Chem 1990; 144 (Suppl. 02) 107-13.
• 18 Kubota K, Matsuzawa T, Takahashi TTF. Rapid and sensitive response of carbon-11-L-methionine tumor uptake to irradiation. J Nucl Med 1989; 30: 2012-6.
• 19 LaFrance N, Links J, Williams J, Holcomb H. Cll-methionine and F18-deoxyglucose (FDG) in the postoperativ management of patients with brain tumors with positron emission tomography. J Nucl Med 1986; 27: P890.
• 20 LaFrance ND, Links J, Williams JHH. Cll-methionine and F18-deoxyglucose (FDG) in the postoperative management of patients with brain tumors with positron emission tomography. J Nucl Med 1986; 27: P890.
• 21 Langen KJ, Coenen HH, Roosen N. et al. SPECT studies of brain tumors with L-3-[¹²³I]iodo-α-methyl tyrosine: Comparison with PET, ¹²⁴IMT and First Clinical Results. J Nucl Med 1990; 31: 281-6.
• 22 Langen KJ, Roosen N, Coenen HH. et al. Brain and brain tumor uptake of L-3-[¹²³I]iodo-α-methyl tyrosine: competition with natural L-amino acids. J Nucl Med 1991; 32: 1225-8.
• 23 Langen KJ, Ziemons K, Kiwit JCW. et al. Quantification of amino acid transport using dynamic I-¹²³-α-methyltyrosin SPECT in patients with brain tumors. Eur J Nucl Med 1994; 21: 789.
• 24 Lim CB, Han KS, Hawman EG, Jaszczak RJ. Image noise, resolution, and lesion detect-ability in single photon emission CT. IEEE Transact Nucl Sei 1982; NS-29: 500-5.
• 25 Machulla HJ, Shanshal A, Stöcklin G. ^123(125) Xe-exposed KIO₃, a reagent for iodination with high specific activity. Radiochim Acta 1977; 24: 42-6.
• 26 McLaughlin WH, Thramann Jr WM, Lambrecht R, Milius RAWB. Preliminary observations of malignant melanoma therapy using radiolabeled alpha-methyltyrosine. J Surg Oncol 1988; 37: 192-7.
• 27 Meyer GJ, Schober O. Uptake of ¹¹C-L- und D-Methionin in brain tumors. Eur J Nucl Med 1985; 10: 373-6.
• 28 Michael H, Rosezin H, Apelt H, Blessing G, Knieper J. Some technical improvements in the production of ¹²³I via the ¹²⁴Te(p,2n) ¹²³I reaction at a compact cyclotron. Int J Appl Radiat Isot 1981; 32: 581-7.
• 29 Ogawa T, Shishido F, Kanno I. et al. Cerebral glioma: Evaluation with methionine PET. Radiology 1993; 186: 45-53.
• 30 Oldendorf WH. Brain uptake of radiolabeled amino acids, amines and hexoses after arterial injection. Am J Physiol 1971; 221 (Suppl. 06) 1629-39.
• 31 Oldendorf WH. Stereospecifity of blood-brain barrier permeability to amino acids. Am J Physiol 1973; 224 No. 4 367-9.
• 32 Patronas NJ, Di Chiro G, Kufta C, Bairamian D. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985; 62: 816-22.
• 33 Roberts S. Influence of elevated circulating levels of amino acids on cerebral concentrations and utilization of amino acids. In: Brain Barrier Systems. Laijtha A, Ford DH. eds. Amsterdam: Elsevier; 1968: 235-43.
• 34 Schober O, Assmann S, Wagner W. et al. The assessment of ¹²³I-α-methyltyrosine (IMT) in the follow up of primary brain tumors. Eur J Nucl Med 1994; 21: 789.
• 35 Schober O, Meyer GJ, Duden C, Lauenstein L. Die Aufnahme von Aminosäuren in Hirntumoren mit der Positronen-Emissionstomographie als Indikator für die Beurteilung von Stoffwechselaktivität und Mali-gnität. Fortschr Röntgenstr 1987; 147 (Suppl. 05) 503-9.
• 36 Tisljar U, Kloster G, Ritzl F. Accumulation of radioiodinated L-α-methyltyrosine in pancreas of mice. J Nucl Med 1979; 20: 973-6.
• 37 Udenfriend S, Zaltzman-Nirenberg PTN. Inhibitors of purified beef adrenal tyrosine hydroxylase. Biochem Pharmacol 1965; 14: 837-45.
• 38 Victor SGL. Das maligne Hirngliom - eine katamnestische Studie über 100 operierte Patienten. Zbl Neurochir 1991; 52: 59-68.
• 39 Wagner RF, Brown DG. Unified SNR analysis of medical imaging systems. Phys Med Biol 1985; 30: 498-518.
• 40 Wienhard K, Herholz K, Coenen HH. et al. Increased amino acid transport into brain tumors measured by PET of L-(2-F-18)fluorotyrosine. J Nucl Med 1991; 32: 1338-46.
• 41 Yoshii Y, Komatsu Y, Yamada T, Hyodo A, Kobayashi TN. Malignancy and viability of intraparenchymal brain tumours: correlation between Gd-DTPA contrast MR images and proliferative potentials. Acta Neurochir (Wien) 1992; 117: 187-94.